Targets › ATP
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Mar 2028.
Open in Phaseline: the race on ATP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| David Boulware | Bedaquiline ATP synthase inhibitor | ATP | Phase 2 | Tuberculous Meningitis | Mar 2028 |
Tuberculous Meningitis (1)
small molecule (1)
David Boulware (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.